Does sex affect how patients respond to ASA?

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 6, 2006, Pages 773-

  Murray, Sally ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MALE; META ANALYSIS; NOTE; PRIMARY PREVENTION; SEX DIFFERENCE; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FEMALE; HUMANS; MALE; SEX FACTORS; TREATMENT OUTCOME;

EID: 33645237570     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060122     Document Type: Note

References (3)

1. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
2. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancer 1998;351:1755-62.
3. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendations and rationale. 2002. Agency for Healthcare Research and Quality. Available: www.ahrq.gov /clinic/3rduspstf/ aspirin/asprr.htm (accessed 2006 Jan 26).